Articles tagged with Cancer Medication
A new immunotherapy called pembrolizumab has shown significant benefits in extending the lives of people with advanced head and neck cancer, with a median survival time of 8.4 months compared to 6.9 months on standard treatment. The drug also caused fewer serious side effects than traditional treatments.
Researchers found that vorinostat effectively inhibited HPV DNA amplification and virus production in preclinical experiments. Additionally, the treatment induced programmed cell death in infected cells. The study suggests that HDAC inhibitors could be promising compounds for treating benign HPV infections.
A randomized clinical trial found immunotherapy drug pembrolizumab more effective than standard chemotherapy in treating chemotherapy-resistant head and neck cancer. Patients receiving pembrolizumab had a higher response rate with longer-lasting responses compared to those on standard therapy.
A new combination of venetoclax with standard drugs azacitidine or decitabine has been granted accelerated approval for treating elderly patients with acute myeloid leukemia. The trial showed a 67% overall response rate, with improved efficacy and tolerability compared to traditional hypomethylating agents.
A study found that restricting cancer cells' ability to metabolize sugar makes oncolytic viruses work better, multiplying faster and destroying cancer quicker. This approach may improve how potential cancer drugs are investigated in the lab.
Seven researchers from the University of California, San Diego have been recognized as AAAS Fellows for their groundbreaking work in various fields. Robert Continetti was honored for his novel studies on molecular reaction dynamics, while Farhat Beg received recognition for his contributions to high energy density science.
The LION LBD AI system is designed to assist scientists in the search for cancer-related discoveries by analyzing tens of millions of publications. By identifying indirect associations between entities, it can help researchers make new connections and discover potential links that may have been overlooked.
Researchers have identified a genetic change common to 80% of human melanomas and developed a molecule that targets this change. The molecule binds to melanocortin-1 receptor (MC1R) on the surface of melanoma cells, allowing for imaging and potential therapy delivery.
Researchers have discovered a new way to target drug-resistant tumors by combining EGFR and Aurora Kinase A inhibitors. Elevated levels of TPX2 protein in biopsies can predict tumor susceptibility to combined therapies.
University of Michigan researchers have developed a new building block that can serve as a safer alternative for the development of new medicines. The novel compound is produced using visible light and does not produce harmful metabolites like traditional anilines.
A Chinese scientist designed a DNA origami nanoplatform that carries chemotherapeutic drugs and RNA interference to target and kill multidrug-resistant cancer cells. The platform demonstrates the effectiveness of RNA interference in reducing drug resistance in cancer treatment.
Cancer cells exhibit sneaky movement patterns that allow them to invade adjacent tissue and spread throughout the body. Researchers have found a way to target these movements, using medicines to stop cancer cells in their tracks.
Researchers identified the protein BRD9 as essential for the survival of synovial sarcoma tumours. They developed a new drug that degrades this protein, which is also responsible for driving cancer development, and found it to be effective in blocking tumour progression.
A team of UC San Diego researchers has received a $1 million Stand Up To Cancer grant to test drugs that block signals driving pancreatic cancer growth. The study aims to identify new therapies that can more effectively block tumor growth and metastasis.
A new study reveals LZTR1 as a key regulator of RAS protein signaling, which is central to growth and oncogenesis. The findings provide a molecular explanation for various pathological conditions, including cancers and developmental disorders.
Researchers have created a new drug that targets the colon and limits its exposure, offering hope for treating Familial Adenomatous Polyposis (FAP) and preventing colon cancer. The treatment could be effective in reducing life expectancy by nearly 50% for children with FAP.
A Malaysian survey found that misconceptions about opioids affect pain control among cancer patients, with fears of addiction and immune system damage being the most common barriers. The study highlights the need for improved accessibility to pain relief treatments in low- and middle-income countries.
A comprehensive analysis found a strong inverse relationship between vaping and smoking among youth and young adults. Vaping became more popular around 2014, resulting in accelerated reductions in youth and young adult smoking prevalence.
Researchers at Virginia Tech have discovered a drug that can block the spread of glioblastoma, the deadliest form of brain cancer, by halting the rapid movement of fluid within the body. The breakthrough finding could lead to improved treatment options for patients with glioblastoma.
Researchers discovered that BH4 regulates T cell activity, suppressing inflammation in autoimmune conditions and enhancing responses in cancer. A new therapeutic approach targets the same pathway to treat a range of diseases.
Researchers found that flunarizine can slow down the growth of triple-negative breast cancer in an animal model, and it promotes N-Ras degradation. This approach is quicker and less expensive than traditional drug development strategies.
Patients with biliary tract cancer and small intestine adenocarcinoma have responded well to a combination of dabrafenib and trametinib, surviving longer without disease progression. The median overall survival time was 11.3 months, with some patients surviving up to two years.
Researchers have identified the molecular target of anti-malarial drugs used in cancer treatment, providing a new pathway for potential treatments. A potent form of the drug DC661 has been developed to target PPT1 and slow tumor growth in mice.
A phase I trial of a new drug combination using nivolumab and pixatimod has reported clinical benefit in four out of five patients with microsatellite stable colorectal cancer. The combination is thought to overcome intrinsic resistance to PD-1 inhibitors in MSS CRC, suggesting potential benefits for this patient population.
Researchers have developed a blood test that can detect and classify cancer at its earliest stages by analyzing epigenetic alterations. The approach holds promise of detecting cancer long before symptoms appear, making it easier to treat.
Researchers at MD Anderson Cancer Center report high response rates of 90% among frontline-treated patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The study, led by Naveen Pemmaraju, presents a novel targeted therapy targeting CD-123, a cell surface receptor expressed in BPDCN and other hematologic malignancies.
The combination therapy of NIR178 and spartalizumab has shown activity in non-small cell lung cancer patients, with two complete responses and 14 patients experiencing stable disease. The treatment was well-tolerated, with most side effects being mild to moderate.
Researchers have found a drug combination that made tumors disappear in mice with neuroblastoma, a childhood cancer. The CBL0137/panobinostat combination was more effective than single drug treatments and showed promise for reducing side effects and increasing survival rates.
Researchers found two genomic tests, MammaPrint and BluePrint, can predict patient response to new treatments. These tests identified subgroups of patients with high-risk tumours more likely to respond to specific therapies.
A new drug, IPdR, has been shown to be safe and effective in boosting radiotherapy for patients with various gastrointestinal cancers. The drug, a prodrug that converts into the active IUdR, can be taken orally and creates high levels of IUdR in the bloodstream, making cancer cells more susceptible to radiation.
ZW25, an antibody targeting the HER2 receptor, has shown encouraging anti-tumour activity in patients with advanced cancers driven by HER2. The median time patients survived without disease progression was 6.21 months, and 13 experienced tumour shrinkage.
Researchers have found a new therapeutic target for pancreatic cancer, RIP1 Kinase, which can be used in combination with other immune-boosting therapies to increase survival rates. The study shows that the drug GSK547 helps to mount a more aggressive attack against tumor cells, doubling survival to 50 days in mice.
Researchers have found a potential Achilles' heel in micrometastasis that could be targeted with medications to reduce the risk of full-blown metastasis. Blocking calcium transfer through gap junctions and mTOR pathway results in cancer cell death or growth inhibition.
A groundbreaking new study by UC Davis researchers has found that obesity can hinder immunotherapy treatments, but also improve survival rates in some obese patients. The study discovered that increased leptin levels in obese individuals correlate with enhanced expression of PD-1 checkpoint protein.
Researchers have discovered a gene signature biomarker that can predict which patients will respond to immune therapy based on the extracellular matrix's stiffness around cancer cells. The study suggests that stiffening of the ECM barrier may physically block the immune system.
A Phase II study found a combination of azacitidine and nivolumab therapy resulted in a 33% overall response rate and 22% complete remission rate for patients with relapsed/refractory acute myeloid leukemia. The drug combination was particularly effective in patients who had not previously received hypomethylating agents, with an overa...
Melbourne scientists discovered how mutant p53 promotes cancer development by 'tackling' the normal protein and blocking its protective role. This allows cancer cells to undergo further genetic changes that accelerate tumour growth.
Researchers have identified a drug that inhibits the signalling pathway of enzyme MEKK3, a process contributing to cerebral cavernous malformations (CCM), a leading cause of stroke in young people. A suitable candidate, Ponatinib, is currently used to treat cancer patients and may offer a non-invasive treatment option.
Researchers aim to understand KLF2's role in vascular health and disease, targeting inflammation and narrowing of arteries. The team seeks to develop novel strategies to sustain KLF2 levels and treat cardiovascular disorders.
Researchers have developed a new strategy against HER2-driven lung cancers using tarloxotinib, a potent HER2/EGFR inhibitor that is more active in low-oxygen conditions than existing therapies. This innovative approach has shown significant promise in treating patients with HER2 lung cancer.
A new 'lab on a chip' technology allows for individualized cancer treatments that target specific tumor cells with high specificity. This breakthrough reduces the cost and time required to develop effective treatments, potentially revolutionizing T cell therapy for cancer.
Researchers at Georgia Tech developed an open source decision support tool using machine learning to analyze RNA expression tied to patient outcomes with specific drugs. The system predicted the chemotherapy drug that had provided the best outcome 80 percent of the time, and its accuracy could improve with additional patient records.
Researchers discovered that melanomas produce BRAF proteins that become active complexes with MEK, making them resistant to RAF-inhibiting drugs. Blocking this complex can restore the potency of the therapy.
The CanSUR summer program at Case Western Reserve University School of Medicine will support 32 undergraduates annually in cancer-focused research. The five-year NIH grant will provide a solid foundation in cancer science and laboratory experience.
A study by Washington State University researchers suggests that inhibiting CDK2 activity can alleviate chemotherapy-induced heart damage in rodents. The finding could be used to develop treatment strategies and drugs to reduce heart disease risk in cancer survivors, particularly those treated with doxorubicin.
Researchers at MIT have developed a novel chemical synthesis method that can modify antibiotics, making them more effective against drug-resistant infections. The technique uses an amino acid called selenocysteine as a 'handle' to link peptides and small-molecule drugs.
A team of researchers from the University of North Texas Health Science Center discovered a new approach to combating melanoma by targeting the NGLY1 protein. The study found that when normal cells are inhibited, they survive, but cancer cells with low or no NGLY1 activity die quickly.
Researchers at Dana-Farber Cancer Institute have discovered a previously unknown molecular vulnerability in two rare, aggressive cancer types, synovial sarcoma and malignant rhabdoid tumors. The study identifies the ncBAF complex as a key player in these cancers' proliferation and growth.
A study in mice suggests that targeting pre-cancerous stem cells could prevent bowel cancer in people with familial adenomatous polyposis (FAP), a condition that increases the risk of developing the disease. Researchers found that treating these stem cells with existing cancer drugs, such as cisplatin, can halt tumour development.
Hong Kong University of Science and Technology researchers identified a new mutation, METex14, in 14% of sGBM patients, leading to more aggressive tumor growth. A promising MET kinase inhibitor, PLB-1001, has been shown to target these tumors with remarkable potency.
A new study reveals that states expanding Medicaid from 2011 to 2017 experienced a significant 27% increase in prescriptions for hormonal therapy medications compared to non-expansion states. This rise was attributed to increased access for previously uninsured women who required long-term treatment with these life-saving drugs.
Researchers discovered that a drug inhibiting glutamine metabolism improves certain immune cells' function while suppressing others. Inhibiting glutaminase activity protects against inflammation and disease in mouse models of various conditions.
Researchers identified potential cancer drugs that disrupt normal chromosome division in cancer cells and induce errors when dividing DNA, posing double trouble for tumor growth. This new approach could inform the development of more effective therapies targeting various types of cancers.
Researchers at UT Southwestern Medical Center have identified blood-based biomarkers that may help identify patients at greatest risk of developing autoimmune side effects from immunotherapy. The study found that levels of certain cytokines were particularly low before treatment in patients who developed immune-related adverse events.
A low-fat diet has been shown to increase the survival rate of obese children with acute lymphoblastic leukemia by five times compared to a high-fat diet. This dietary intervention could potentially help kill cancer cells and improve treatment outcomes.
A NUS study found that overexpression of ADAR1 and irregular RNA editing of NEIL1 are key factors in MM progression and drug resistance. The study offers novel insights for new therapeutic strategies.
The partnership aims to reduce cancer health disparities among African-American, Asian-Pacific-American, and Hispanic-American communities in the NYC-Philadelphia corridor. It will focus on multidisciplinary research, community outreach, and education to improve quality of life and health outcomes.
Researchers at the University of Cincinnati have developed a molecular diagnostic test that can assess breast cancer risk based on Osteopontin variants. The test helps patients and doctors make informed decisions about treatment options, weighing aggressive intervention against waiting for potential progression.
A small observational study suggests that rose geranium oil spray can help alleviate nasal vestibulitis, a common and painful condition caused by cancer drug treatment. The study found that 55% of participants experienced moderate benefit from using the oil, with some reporting complete symptom resolution.
A small study found that rose geranium oil spray in sesame oil base helped reduce the severity of nasal vestibulitis symptoms, which are common side effects of chemotherapy. The oil was used by 20 women on chemotherapy, with most reporting moderate to substantial benefits.